Most Popular Stories
Poll
Featured Jobs
-
Tennessee Family Practice
StaffPointe, LLC - near Memphis , TN -
Pennsylvania Laboratory Manager
StaffPointe, LLC - Philadelphia, PA -
Washington Outpatient Physical Therapy
StaffPointe, LLC - Federal Way, WA -
Florida Psych NP
StaffPointe, LLC - south , FL -
Washington Home Healthcare PT
StaffPointe, LLC - central, WA
Events
- Fall Health IT Summit
Oct 27-28 — Los Angeles, CA - Free Webcast: Management Lessons from Mayo Clinic
Oct 30, 12pm EDT - World Health Care Congress
April 14-16, 2009 — Washington, DC
Paid Research Reports
- Stakeholder Opinions: Percutaneous Coronary Intervention - Adverse events with drug-eluting stents demand a new safety standard
- Impact of Pharmacogenomics on Public Healthcare Policy
- The Cardiovascular Disorders Market Outlook to 2012
- 2008 Trends to Watch: Pharmaceutical Technology
- Pharmaceutical Pricing and Reimbursement: Strategies for market access across the US, Europe, Japan and other key geographies
Popular Topics
CT Attorney General sues FDA over OxyContin
Following on years of attempts to urge the FDA into action, Connecticut Attorney General Richard Blumenthal has filed a suit in federal court that attempts to force the FDA to issue stronger warnings about OxyContin dosing. In 2003, Blumenthal mounted an investigation into the drug's labeling and use, concluding that while the drug is designed for 12-hour dosing, drug maker Purdue Pharma knew that 20 percent of the time, it was prescribed to be used in dosing intervals of eight hours or less. The next year, Blumenthal filed a "citizen petition" with the FDA asking that it issue warnings related to OxyContin dosing, but the FDA didn't respond as he had hoped. The new lawsuit asks the court to find that the FDA's failure to respond to the petition was unlawful, and forces it to issue stronger warnings on OxyContin prescribing. Purdue already has been hit with more than $600 million in fines after regulators concluded that it had misrepresented the risks of using the drug.
To learn more about the case:
- read this press release
Related Stories
- Pharmas may be able to drag suits to federal court
- FDA to further investigate anemia drug risks
- Avandia gets black-box warning
- FTC: Pharmas cut 14 deals to delay generic sales in '07
- Serious nursing home quality problems still exist
- Reports suggest that Merck downplayed Vioxx risks
- FDA says Glaxo didn't report Avandia data
- Number of heparin-related deaths reported triples
- Decision allows Warner-Lambert suit to continue
- Senate questions device maker payments to surgeons
Comments
Post new comment
Home
| Subscribe | Advertise | Mobile Edition | RSS |
Privacy
| Site MapTHE FIERCEMARKETS NETWORKFierceFinance | FierceFinanceIT | FierceSarbox | FierceHealthcare | FierceHealthFinance | FierceHealthIT | Hospital Impact | FierceCIO | FierceCIO:TechWatch | FierceContentManagement | FierceMobileIT | FierceBiotech | FierceBioResearcher | FiercePharma | FierceVaccines | FierceIPTV | FierceOnlineVideo | FierceTelecom | FierceVoIP | FierceBroadbandWireless | FierceDeveloper | FierceMobileContent | FierceWireless | FierceWireless:Europe© 2008 FierceMarkets, Inc. All rights reserved. |
![]() |





